Aphton Cancer Company Intelligence Report

Pharma Business Daily
Claim your FREE trial subscription!

Cancer:

Aphton Cancer Company Intelligence Report

Espicom Business Intelligence
Market Briefing September 2005

curring hormone, and gastrin receptors. It is well documented in scientific literature that gastrin and gastrin receptors are critical to the onset, development, growth and spread of adenocarcinomas of the GI system, including those found in the stomach, pancreas, oesophagus, liver and throughout the colon and rectum.

Aphton is engaged in the research and development and clinical trials of its products, both independently and through various strategic alliances. It has financed its operations primarily through the sale of its equity securities.

Aphton’s approach to the treatment of major diseases is to employ (anti) hormone therapy. Aphton’s hormone therapy involves blocking certain hormones that play a critical role in these diseases. This is accomplished by immunising the patients with an immunogen that induces in them a directed Ab response which neutralises, and removes from circulation, the targeted hormone.

Number of pages - 18

For full details, please email keithw@cmsinfo.com

Order Form

CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: Jennifer Cowlard

For more information about us, visit CMSinfo.